Colon Cancer Home > Zaltrap and Breastfeeding
The manufacturer of Zaltrap (ziv-aflibercept) recommends that women not breastfeed during chemotherapy with this drug. Although it is unknown if this drug passes through breast milk, it might put a nursing infant at risk for problems. Because every woman's situation is different, talk to your healthcare provider about the benefits and risks of using Zaltrap while breastfeeding.
Zaltrap® (ziv-aflibercept) is a prescription medication approved for use in combination with other medicines to treat metastatic colorectal cancer (cancer of the colon or rectum that has spread to other areas of the body). At this time, it is unknown whether Zaltrap passes through breast milk. The manufacturer of the medicine recommends it not be used in breastfeeding women.
There is very little information available on using Zaltrap while breastfeeding. The medication has not been adequately studied in women who are nursing. Therefore, it is unknown whether the drug passes through breast milk, or if it would harm a nursing child.
Although this lack of information is certainly frustrating, it is important to note that most medicines are not studied in breastfeeding women. This is because such studies would potentially expose a nursing child, who would otherwise usually not benefit from the medicine, to possible risks.
You should discuss breastfeeding and Zaltrap use with your healthcare provider. Each woman's situation is different, and you and your healthcare provider understand your situation best. After considering what you want and expect, as well as your current health situation, the two of you can make a shared decision that is right for you.